Pharmacology effects and side effects

Clinical Assessment and Intervention for Autism Spectrum Disorders

Volumn , Issue , 2008, Pages 221-263

  Lecavalier, Luc ^a   Gadow, Kenneth ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58549095371     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012373606-2.50010-3     Document Type: Chapter

References (154)

1. Achenbach T.M., McConaughy S.H., Howell C.T. Child/adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychological Bulletin 1987, 101:213-232.
2. Aman M.G. Annotated further-reading on the Aberrant Behavior Checklist (June 2003 update) 2003, Ohio State University, Columbus, OH.
3. Aman M.G., Arnold E., McDougle C.J., et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology 2005, 15:869-884.
4. Aman M.G., DeSmedt G., Derivan A., et al. Double-blind, placebo-controlled study of Risperidone for the treatment of Disruptive Behaviors in Children with Sub average Intelligence. American Journal of Psychiatry 2002, 159:1337-1346.
5. Aman M.G., Lam K.L., Collier-Crespin A. Prevalence and patterns of use of psy- choactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders 2003, 33:527-534.
6. Aman M.G., Lam K.S.L., Van Bourgondien M.E. Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology 2005, 15:116-126.
7. Aman M.G., Novotny S., Samango-Sprouse C., et al. Outcome measures for clinical trials in autism. Central Nervous System Spectrum 2004, 9:36-47.
8. Aman M.G., Sarphare G., Burrow W. Psychoactive drugs in group homes: Prevalence and relation to demographic/psychiatric variables. American Journal of Mental Retardation 1995, 99:500-509.
9. Aman M.G., Singh N.N. Aberrant Behavior Checklist-Community. Supplementary Manual 1994, Slosson Educational Publications, East Aurora, NY.
10. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency 1985, 89:485-491.
11. Aman M.G., Singh N.N., Stewart A.W., Field C.J. Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency 1985, 89:492-502.
12. Aman M.G., Tassé M.J., Rojahn J., Hammer D. The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities 1996, 17:41-57.
13. Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Author, Washington, DC. 4th ed.
14. Ando H., Yoshimura I. Effects of age on communication skill levels and prevalence of maladaptive behaviors in autistic and mentally retarded children. Journal of Autism and Developmental Disorders 1979, 9:83-93.
15. Arnold L.E., Aman M.G., Cook A.M., et al. Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45:1196-1205.
16. Barnes T.R.E. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989, 154:672-676.
17. Bird H.R., Gould M.S., Staghezza B. Aggregating data from multiple informants in child psychiatry epidemiological research. Journal of the American Academy of Child and Adolescent Psychiatry 1992, 31:78-85.
18. Bodfish J.W., Symons F.W., Lewis M.H. The Repetitive Behavior Scale. Western Carolina Center Research Reports 1999.
19. Bodfish J.W., Symons F.J., Parker D.E., Lewis M.H. Varieties of repetitive behavior in autism: Comparisons to mental retardation. Journal of Autism and Developmental Disorders 2000, 30:237-243.
20. Bradley C. Characteristics and management of children with behavior problems associated with organic brain damage. Pediatric Clinics of North America 1957, 4:1049-1060.
21. Brereton A.V., Tonge B.J., Mackinnon A.J., Einfeld S.L. Screening young people for autism with the Development Behavior Checklist. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:1369-1375.
22. Brown E.C., Aman M.G., Havercamp S.M. Factor analysis and norms on parent ratings with the Aberrant Behavior ChecklistCCommunity for young people in special education. Research in Developmental Disabilities 2002, 23:45-60.
23. Brown E., Aman M.G., Lecavalier L. Empirical classification of behavioral and psychiatric problems in children and adolescents with mental retardation. American Journal on Mental Retardation 2004, 109:445-455.
24. Campbell M., Palij M. Measurement of side effects including tardive dyskinesia. Psychopharmacology Bulletin 1985, 9(Special Issue):1063-1082.
25. Chung S.Y., Luk S.L., Lee P.W. A follow-up study of infantile autism in Hong Kong. Journal of Autism and Developmental Disorders 1990, 20:221-232.
26. Cichetti D.V. Guidelines, criteria, and rule of thumb for evaluating normed and standardized assessment instruments in psychology. Psychological Assessment 1994, 6:284-290.
27. Clark A.R., Tonge B.J., Einfeld S.L., Mackinnon A. Assessment of change with the Developmental Behaviour Checklist. Journal of Intellectual Disability Research 2003, 47:210-212.
28. Coccaro E.F., Harvey P.D., Kupsaw-Lawrence E., et al. Development of neurophar- macologically based behavioural assessments of impulsive aggressive behaviour. Journal of Neuropsychiatry and Clinical Neuroscience 1991, 3:s44-s51.
29. Cohen I.L. Criterion-related validity of the PDD Behavior Inventory. Journal of Autism and Developmental Disorders 2003, 33:47-53.
30. Cohen I.L., Schmidt-Lackner S., Romanczyk R., Sudhalter V. The PDD Behavior Inventory: A rating scale for assessing response to intervention in children with pervasive developmental disorder. Journal of Autism and Developmental Disorders 2003, 33:31-45.
31. Cohen I.L., Sudhalter V. The PDD Behavior Inventory 2005, Psychological Assessment, Lutz, FL.
32. Collett B.R., Ohan J.L., Meyers K.M. Ten-year review of rating scales. VI: Scales assessing externalizing behaviors. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:1143-1170.
33. Depue R.A., Slater J.F., Wolfstetter-Kausch H., et al. A behavioral paradigm for identifying persons at risk for bipolar depressive disorder: A conceptual framework and five validation studies. Journal of Abnormal Psychology 1981, 90:381-437.
34. DeVincent C.J., Gadow K.D., Delosh D., Geller L. Sleep disturbance and its relation to DSM-IV psychiatric symptoms in preschool-aged children with pervasive developmental disorder and community controls. Journal of Child Neurology 2007, 22:161-169.
35. Drabick, D.A.G., Gadow, K.D., and Loney, J. (in press). Co-occurring ODD and GAD symptom groups: Source-specific syndromes and cross-informant comorbidity. Journal of Clinical Child and Adolescent Psychology.
36. Drabick D.A.G., Gadow K.D., Loney J. Source-specific oppositional defiant disorder: Comorbidity and risk factors in referred elementary school boys. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46:92-101.
37. Einfeld S.L., Tonge B.J. Manual for the Developmental Behaviour Checklist 1992, Monash University Center for Developmental Psychiatry and School of Psychiatry, University of New South Wales, Clayton, Malbourne, and Aydney.
38. Einfeld S.L., Tonge B.J. Manual for the Developmental Behaviour Checklist (Second Edition) 2002, Monash University Center for Developmental Psychiatry and School of Psychiatry, University of New South Wales, Clayton, Malbourne, and Sydney.
39. Ellis M.J., Witt P.A., Reynolds R., Sprague R.L. Methylphenidate and the activity of hyperactives in informal settings. Child Development 1974, 45:217-220.
40. Esbensen A.J., Rojahn J., Aman M.G., Ruedrich S. The reliability and validity of an assessment instrument for anxiety, depression and mood among individuals with mental retardation. Journal of Autism and Developmental Disorders 2003, 33:617-629.
41. Eyman R.K., Borthwick S.A., Miller C. Trends in maladaptive behavior of mentally retarded persons placed in community and institutional settings. American Journal of Mental Deficiency 1981, 85:473-477.
42. Feighner J.P., Robins E., Guze S.B., et al. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 1972, 26:57-63.
43. Gadow K.D. Stimulant Side Effects Checklist 1986, Department of Psychiatry, State University of New York, Stony Brook.
44. Gadow K.D. Clinical issues in child and adolescent psychopharmacology. Journal of Consulting and Clinical Psychology 1991, 59:842-852.
45. Gadow K.D., DeVincent C.J. Clinical significance of tics and attention-deficit hyper- activity disorder (ADHD) in children with pervasive developmental disorder. Journal of Child Neurology 2005, 20:481-488.
46. Gadow K.D., DeVincent C.J., Drabick D.A.G. Oppositional Defiant Disorder as a Clinical Phenotype in Children with Pervasive Developmental Disorder 2007, Manuscript submitted for publication.
47. Gadow K.D., DeVincent C., Pomeroy J. ADHD symptom subtypes in children with pervasive developmental disorder. Journal of Autism and Developmental Disorders 2006, 36:271-283.
48. Gadow K.D., DeVincent C.J., Pomeroy J., Azizian A. Psychiatric symptoms in preschool children with PDD and clinic and comparison samples. Journal of Autism and Developmental Disorders 2004, 34:379-393.
49. Gadow K.D., DeVincent C.J., Pomeroy J., Azizian A. Comparison of DSM-IV symptoms in elementary school-aged children with PDD versus clinic and community samples. Autism 2005, 9:392-415.
50. Gadow K.D., DeVincent C., Schneider J., Drabick D.A.G. Predictors of psychiatric syndromes in children with autism spectrum disorders 2007, Manuscript submitted for publication.
51. Gadow K.D., Drabick D.A.G., Loney J., et al. Comparison of ADHD symptom subtypes as source-specific syndromes. Journal of Child Psychology and Psychiatry 2004, 45:1135-1149.
52. Gadow K.D., Paolicelli L.M., Nolan E.E., et al. Methylphenidate in aggressive hyperactive boys: II. Indirect effects of medication on peer behavior. Journal of Child and Adolescent Psychopharmacology 1992, 2:49-61.
53. Gadow K.D., Sverd J., Sprafkin J., et al. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Archives of General Psychiatry 1995, 52:444-455.
54. Gadow K.D., Pomeroy J.C. A controlled case study of methylphenidate and fenfluramine in a young mentally retarded, hyperactive child. Australian and New Zealand Journal of Developmental Disabilities 1990, 16:323-334.
55. Gadow K.D., Sprafkin J. Early Childhood Inventory-4 norms manual 1994, Checkmate Plus, Stony Brook, NY.
56. Gadow K.D., Sprafkin J. Adolescent Symptom Inventory-4 screening manual. 1997, Checkmate Plus, Stony Brook, NY.
57. Gadow K.D., Sprafkin J. Early Childhood Inventory-4 screening manual 2000, Checkmate Plus, Stony Brook, NY.
58. Gadow K.D., Sprafkin J. Child Symptom Inventory-4 Screening and Norms Manual 2002, Checkmate Plus, Stony Brook, NY.
59. Gadow K.D., Sprafkin J. The Symptom Inventories: An Annotated further-reading 2006, [On-line]. Available. http://www.checkmateplus.com.
60. Gadow K.D., Sprafkin J., Schneider J., et al. ODD, ADHD, versus ODD + ADHD in clinic and community adults. Journal of Attention Disorders 2007, 11:374-383.
61. Gadow K.D., Sprafkin J., Weiss M. Adult Self Report Inventory-4 and Adult Inventory-4 manual 2004, Checkmate Plus, Stony Brook, NY.
62. Ghaziuddin M., Greden J. Depression in children with autism/pervasive developmental disorders: A case-control family history study. Journal of Autism and Developmental Disorders 1998, 28:111-115.
63. Gillberg C., Billstedt E. Autism and Asperger syndrome: Coexistence with other clinical disorders. Acta Psychiatrica Scandinavica 2000, 102:321-330.
64. Goodman W.K., Price L.H., Rasmussen S.A., et al. The Yale-Brown obsessive compulsive scale, II: Validity. Archives of General Psychiatry 1989, 46:1012-1016.
65. Goodman W.K., Price L.H., Rasmussen S.A., et al. The Yale-Brown Obsessive Compulsive Scale, I: Development, use, and reliability. Archives of General Psychiatry 1989, 46:1006-1011.
66. Green J., Gilchrist A., Burton D., Cox A. Social and psychiatric functioning in adolescents with Asperger syndrome compared with conduct disorder. Journal of Autism and Developmental Disorder 2000, 30:279-293.
67. Handen B.L., Feldman H., Gosling A., et al. Adverse effects of methylphenidate among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 1991, 30:241-245.
68. Handen B.L., Johnson C.R., Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders 2000, 30:245-255.
69. Handen B.L., Lubetsky M. Pharmacotherapy in Autism and Related Disorders. School Psychology Quarterly 2005, 20:155-171.
70. Hellings J.A., Nickel E.J., Weckbaugh M., et al. The overt aggression scale for rating aggression in outpatient youth with autistic disorder: Preliminary findings. Journal of Neuropsychiatric & Clinical Neurosciences 2005, 17:29-35.
71. Hellings J.A., Weckbaugh M., Nickel E.J., et al. A double-blind, placebo-controlled study of Valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 2005, 15:682-692.
72. Holden B., Gitlesen J.P. A total population study of challenging in the county of Hedmark, Norway: Prevalence, and risk markers. Research in Developmental Disabilities 2006, 27:456-465.
73. Hollander E., Wasserman S., Swanson E.N., et al. A double-blind placebo-controlled pilot study of alanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology 2006, 16:541-548.
74. Kalachnik J. Assessment sheet for Monitoring of Side Effects System (MOSES). Drug Therapy for Behavior Disorders: An Introduction 1986, 153-155. Pergamon Press, New York. A. Poling, K. Gadow, J. Cleary (Eds.).
75. Kalachnik J.E. Measureing side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Review 1999, 5:348-359.
76. Kim J.A., Szatmari P., Bryson S., et al. The prevalence of anxiety and mood problems among children with autism and Asperger syndrome. Autism 2000, 4:117-132.
77. Lam, K.L.S. and Aman, M.G. (in press). The repetitive behavior scale-revised: Independent validation in individuals with autism spectrum disorders. Journal of Autism and Developmental Disorders, 37, 855-866.
78. Langworthy-Lam K.L., Aman M.G., Van Bourgondiem M.E. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology 2002, 12:311-321.
79. LeBlanc L.A., Matson J.L., Cherry K.E., Bamburg J.W. An examination of the convergent validity of the Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER) with sociometric ranking. British Journal of Developmental Disabilities 1999, 45:85-91.
80. Lecavalier L. Behavior and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders 2006, 36:1101-1114.
81. Lecavalier L., Aman M.G. Rating instruments. In Behavior Modification for Persons with Developmental Disabilities: Treatments and Supports: Volume One 2005, 160-189. National Association for the Dually Diagnosed Press, Kingston, NY. J.L. Matson, R.B. Laud, M.L. Matson (Eds.).
82. Lecavalier L., Aman M.G., Hammer D., et al. Factor analysis of the nisonger child behavior rating form in children with autism spectrum disorders. Journal of Autism and Developmental Disorders 2004, 34:709-721.
83. Lecavalier L., Leone S., Wiltz J. The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. Journal of Intellectual Disability Research 2006, 50:172-183.
84. Ledford J.R., Gast D.L. Feeding problems in children with autism spectrum disorders: A review. Focus on Autism and Other Developmental Disabilities 2006, 21:153-166.
85. Leyfer O.T., Folstein S.E., Bacalman S., et al. Comorbid psychiatric disorders in children with autism: Interview developmental rates of disorders. Journal of Autism and Developmental Disorders 2006, 36:849-861.
86. Malone R.P., Gratz S.S., Delaney M.A., Hyman S.B. Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs 2005, 19:923-934.
87. Marshburn E.C., Aman M.G. Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. Journal of Autism and Developmental Disorders 1992, 22:357-373.
88. Martin A., Scahill L., Klin A., Volkmar F.R. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. Journal of the American Academy of Child and Adolescent Psychiatry 1999, 38:923-931.
89. Matson J.L. Manual for the Matson Evaluation of Social Skills for Individuals with Severe Retardation 1995, Scientific Publishers, Inc., Baton Rouge, LA.
90. Matson J.L. Manual for the Diagnostic Assessment for the Severely Handicapped-II 1998, Louisiana State University, Baton Rouge, LA.
91. Matson J.L. Manual for the Assessment of Dual Diagnosis 1997, Louisiana State University, Baton Rouge, LA.
92. Matson J.L., Baglio C.S., Smiroldo B.B., et al. Characteristics of autism as assessed by the Diagnostic Assessment for the Severely Handicapped-II (DASH-II). Research in Developmental Disabilities 1996, 17:1-9.
93. Matson J.L., Bamburg J.A. Reliability of the Assessment of Dual Diagnosis (ADD). Research in Developmental Disabilities 1998, 19:89-95.
94. Matson J.L., Carlisle C.B., Bamburg J.W. The convergent validity of the Matson Evaluation of Social Skills for individuals with Severe Retardation. Research in Developmental Disabilities 1998, 19:493-500.
95. Matson J.L., Hamilton M., Duncan D., et al. Characteristic of stereotypic movement disorder and self-injurious behavior as assessed by the Diagnostic Assessment for the Severely Handicapped II (DASH-II). Research in Developmental Disabilities 1997, 18:457-469.
96. Matson J.L., Laud R.B., Gonzalez M.L., et al. The reliability of the scale for the evaluation and identification of seizure, epilepsy, and anticonvulsant side Effects-B (SEIZES B). Research in Developmental Disabilities 2005, 26:593-599.
97. Matson J.L., LeBlanc L.A., Weinheimer B. Reliability of the Matson Evaluation of Social Skills in Individuals with Severe Retardation (MESSIER). Behavior Modification 1999, 23:647-661.
98. Matson J.L., Mayville E.A., Bielecki J., et al. Reliability of the Matson Evaluation of Drug Side Effects (MEDS). Research in Developmental Disabilities 1998, 19:501-506.
99. Matson J.L., Rush K.S., Smiroldo B.B., et al. Characteristics of depression as assessed by the Diagnostic Assessment for the Severely Handicapped II (DASH-II). Research in Developmental Disabilities 1999, 20:305-313.
100. Matson J.L., Smiroldo B.B. Validity of the mania subscale of the Diagnostic Assessment for the Severely Handicapped-II (DASH-II). Research in Developmental Disabilities 1997, 18:1-5.
101. Matson J.L., Smiroldo B.B., Hamilton M., Baglio C.S. Do anxiety disorders exist in people with severe and profound mental retardation?. Research in Developmental Disabilities 1997, 18:39-44.
102. McClintock J., Hall S., Oliver C. Risk markers associated with challenging behaviours in people with intellectual disabilities: A meta-analytic study. Journal of Intellectual Disability Research 2003, 47:405-416.
103. McDougle C.J., Scahill L., Aman M.G., et al. Risperidone for the core symptom domains of autism: Results from the study by the autism network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry 2005, 162:1142-1148.
104. Meyers K., Winters N.C. Ten-year review of rating scales, I: Overview of scale functioning, psychometric properties, and selection. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:114-122.
105. Meyers K., Winters N.C. Ten-year review of rating scales, II: Scales for internalizing disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:634-659.
106. Muris P., Steerneman P., Merckelbach H., et al. Comorbid anxiety symptoms in children with pervasive developmental disorders. Journal of Anxiety Disorders 1998, 12:387-393.
107. Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology Revised 1976, 217-222. National Institute of Mental Health, U.S. National Institutes of Health, Psychopharmacology Research Branch, Rockville, MD. W. Guy (Ed.).
108. Nolan E.E., Gadow K.D. Children with ADHD and tic disorder and their classmates: behavioral normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36:597-604.
109. Nolan E.E., Gadow K.D., Sprafkin J. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics 1999, 103:730-737.
110. Nolan E.E., Gadow K.D., Sprafkin J. Teacher reports of DSM-IV ADHD, ODD, and CD symptoms in schoolchildren. Journal of the American Academy of Child and Adolescent Psychiatry 2001, 40:241-249.
111. Offord D.R., Boyle M.H., Racine Y., et al. Integrating assessment data from multiple informants. Journal of the American Academy of Child and Adolescent Psychiatry 1996, 35:1078-1085.
112. Pearson D.A., Aman M.G. Ratings of hyperactivity and developmental indices: Should clinicians correct for developmental level?. Journal of Autism and Developmental Disorders 1994, 24:395-411.
113. Piacentini J.C., Cohen P., Cohen J. Combining discrepant diagnostic information from multiple sources: A re complex algorithms better than simple ones?. Journal of Abnormal Child Psychology 1992, 20:51-63.
114. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine 2002, 347:314-321. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network.
115. The Pedi-atric Anxiety Rating Scale (PARS): Development and psychometric properties. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:1061-1069. Research Units on Pediatric Psychopharmacology (RUPP) Anxiety Study Group.
116. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyper-activity. Archives of General Psychiatry 2005, 62:1266-1274. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network.
117. Robins E., Guze S. Establishment of diagnostic validity in psychiatric illness: Its application to schizophrenia. American Journal of Psychiatry 1970, 126:983-987.
118. Rojahn J., Tassé M.J. Psychopathology in mental retardation. Manual of Diagnosis and Professional Practice in Mental Retardation 1996, 147-156. APA, Washington DC. J.W. Jacobson, J.A. Mulick (Eds.).
119. Rojahn J., Matson J.L., Lott D., et al. The behavior problems inventory: An instrument for the assessment of self-injury, stereotyped behavior and aggression/destruction in individuals with developmental disabilities. Journal of Autism and Developmental Disorders 2001, 31:577-588.
120. Rutter M., Greenfield D., Lockyer L. A five to fifteen year follow-up study of Infantile Psychosis: II. Social and behavioral outcome. British Journal of Psychiatry 1967, 113:1183-1190.
121. Scahill L., Lord C. Subject selection and characterization in clinical trials in children with autism. CNS Spectrums 2004, 9:22-32.
122. Scahill L., McDougle C.J., Williams S.K., et al. Children's Yale-Brown obsessive compulsive scale modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45:1114-1123.
123. Scahill L., Riddle M.A., McSwiggin-Hardin M., et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36:844-852.
124. Shaffer D., Gould M.S., Brasic J., et al. A children's global assessment scale (CGAS). Archives of General Psychiatry 1983, 40:1228-1231.
125. Simmons J.M. Observations on compulsive behavior in autism. Journal of Autism and Childhood Schizophrenia 1974, 4:1-10.
126. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970, 212:11-19.
127. Snyder R., Turgay A., Aman M.G., et al. Effects of risperidone on conduct and disruptive disorders in children with subaverage IQ's. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:1026-1036.
128. Sofronoff K., Attwood T., Hinton S. A randomized controlled trial of a CBT intervention for anxiety in children with Asperger syndrome. Journal of Child Psychology and Psychiatry 2005, 46:1152-1160.
129. Sorgi P., Ratey J., Knoedler D.W., et al. Rating aggression in the clinical setting. A retrospective adaptation of the overt aggression scale: Preliminary results. Journal of Neuropsychiatry 1991, 3:S52-S56.
130. Sparrow S., Balla D., Cichetti D. The Vineland Adaptive Behavior Scales: Interview Edition, Survey Form 1984, American Guidance Service, Circle Pines, MN.
131. Sparrow S., Cicchetti D., Balla D. The Vineland Adaptive Behavior Scales Second Edition, Survey Forms Manual 2005, American Guidance Service, Circle Pines, MN.
132. Sprafkin J., Gadow K.D. Double-blind versus open evaluations of stimulant drug response in children with attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 1996, 6:215-228.
133. Sprafkin J., Gadow K.D., Nolan E.E. The utility of a DSM-IV-referenced screening instrument for attention-deficit/hyperactivity disorder. Journal of Emotional and Behavioral Disorders 2001, 9:182-191.
134. Sprafkin J., Gadow K.D., Salisbury H., et al. Further evidence of reliability and validity of the Child Symptom Inventory-4: Parent Checklist in clinically referred boys. Journal of Clinical Child and Adolescent Psychology 2002, 31:513-524.
135. Sprafkin J., Gadow K.D., Weiss M.D., et al. Psychiatric comorbidity in ADHD symptom subtypes in clinic and community adults. Journal of Attention Disorders 2007, 11:114-124.
136. Sturmey P., Matson J.L., Lott J.D. The factor structure of the DASH-II. Journal of Developmental and Physical Disabilities 2004, 16:247-255.
137. Sukhodolsky D.G., Scahill L., Gadow K.D., et al. Parent-rated anxiety symptoms in children with pervasive developmental disorders: Frequency and association with core autism symptoms and cognitive functioning. Journal of Abnormal Child Psychology 2007.
138. Sverd J. Psychiatric disorders in individuals with pervasive developmental disorder. Journal of Psychiatric Practice 2003, 9:111-127.
139. Tassé M.J., Aman M.G., Hammer D., Rojahn J. The Nisonger child behavior rating form: Age and gender effects and norms. Research in Developmental Disorders 1996, 17:59-75.
140. Tuchman R. AEDs and psychotropic drugs in children with autism and epilepsy. Mental Retardation and Developmental Disabilities 2004, 10:135-138.
141. Tonge B.J., Einfeld S.L. Psychopathology and intellectual disability: The Australian child to adult longitudinal study. International Review of Research in Mental Retardation 2003, Vol. 26:61-91. Academic Press, San Diego, CA. L.M. Glidden (Ed.).
142. Valdovinos M.G., Schroeder S.R., Kim G. Prevalence and correlates of psychotropic medication use among adults with developmental disabilities: 1970-2000. International Review of Research in Mental Retardation 2003, 175-220. Academic Press, San Diego, CA. L.M. Glidden (Ed.).
143. Wagner A., Lecavalier L., Arnold L.E., et al. Developmental Disabilities Modification of Children's Global Assessment Scale (DD-CGAS). Biological Psychiatry 2007, 61:504-511.
144. Watson J.E., Aman M.G., Singh N.N. The psychopathology instrument for mentally retarded adults: Psychometric characteristics, factor structure, and relationship to subject characteristics. Research in Developmental Disabilities 1988, 9:277-290.
145. Weisbrot D.M., Gadow K.D., DeVincent C.J., Pomeroy J. The presentation of anxiety in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 2005, 15:477-496.
146. Whalen C.K., Collins B.E., Henker B., et al. Behavior observations of hyperactive children and methylphenidate (Ritalin) effects in systematically structured classroom environments: Now you see them, now you don't. Journal of Pediatric Psychology 1978, 3:177-184.
147. Whalen C.K., Henker B., Collins B.E., et al. A social ecology of hyperactive boys: Medication effects in structured classroom environments. Journal of Applied Behavioral Analysis 1979, 12:65-81.
148. Williams S.K., Scahill L., Vitiello B., et al. Risperidone and Adaptive Behavior in Children with Autism. Journal of the American Academy of Childand Adolescent Psychiatry 2006, 45:431-439.
149. Wing L. Asperger's syndrome: a clinical account. Psychological Medicine 1981, 11:115-129.
150. Witwer A., Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. Journal of Child and Adolescent psychopharmacology 2005, 15:671-681.
151. Winters N.C., Collett B.R., Myers K.M. Ten-year review of rating scales, VII: scales assessing functional impairment. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44:309-338.
152. Wozniak J., Biederman J., Faraone S.V., et al. Mania in children with pervasive developmental disorder revisited. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36:1552-1559.
153. Youngstrom E.A., Findling R.L., Danielson C.K., Calabrese J.R. Discriminative validity of parent report of hypomanic and depressive symptoms on the General Behavior Inventory. Psychological Assessment 2001, 13:267-276.
154. Yudofsky S.C., Silver J.M., Jackson W., et al. The Overt Aggression Scale or the objective rating of verbal and physical aggression. American Journal of Psychiatry 1986, 143:35-39.